FilingSEC EDGAR8-K
Phio Pharmaceuticals Completes First Commercial-Scale cGMP Batch of PH-762
· SEC accepted
Stagemanufacturing milestone
Filing content
The company successfully completed the first commercial-scale cGMP batch of its PH-762 drug substance, supporting its plan to initiate a Phase 2b clinical trial in the first quarter of 2027.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…